Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Mycology, chemical components, bioactivities, and fermentation process regulation of Sanghuang: a review].
Zhongguo Zhong Yao Za Zhi
December 2024
Mycomedicine Research Laboratory, School of Pharmaceutical Science, Hunan University of Chinese Medicine Changsha 410208, China Tertiary Research Lab of TCM Property & Efficacy,National Administration of TCM Changsha 410208, China.
Sanghuang, a famous ethnomedicine widely used in China, Japan, Korea and other countries for a long history, is produced from the dried fruiting bodies of the medical fungi belonging to Sanghuangporus. With abundant bioactive natural chemicals including polysaccharides, flavonoids, triterpenoids, and polyphenols, Sanghuang exhibits anticancer, antioxidant, blood glucose-and lipid-lowering, liver protecting, anti-inflammatory, antimicrobial, and gout symptom-relieving effects, thus demonstrating broad application and development prospects in the pharmaceutical and food fields. However, the sustainable development of Sanghuang resources is limited by the scarce stock of wild resources, the diverse original fungi of cultivated Sanghuang, the inconsistency of local standards of Sanghuang materials or products, and the lagging application of Sanghuangporus mycelia.
View Article and Find Full Text PDFEfficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trial.
Lancet Reg Health Eur
January 2025
Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.
Article Synopsis
- The study focuses on the effectiveness of a sublingual immunotherapy (SLIT) tablet for treating house dust mite-induced allergic rhinitis in children aged 5-11 years, addressing a gap in existing data for this age group.
- Conducted as a Phase III randomized trial, 1460 children were divided into two groups: one receiving the SLIT tablet and the other receiving a placebo, with significant improvements observed in allergy symptoms and quality of life for the SLIT group.
- Results showed a notable 22% reduction in the total combined rhinitis score for the SLIT group compared to placebo, alongside improved scores in other related outcome measures, suggesting SLIT's potential as an effective
The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children-A pivotal phase III trial.
Allergy
November 2024
Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.
Background: Allergic rhinitis and/or conjunctivitis (AR/C) induced by tree pollen is common and negatively impacts quality of life in children and adolescents. This phase III trial investigated the efficacy and safety of the SQ tree SLIT-tablet in a paediatric population (5-17 years) with moderate-to-severe AR/C induced by pollen from birch and trees in the birch homologous group.
Methods: Nine hundred and fifty-two subjects were randomized (1:1) to daily treatment with SQ tree SLIT-tablet or placebo for up to 52 weeks and had free access to AR/C symptom-relieving medications.
Use and safety of peripherally inserted central catheters and midline catheters in palliative care cancer patients: a retrospective review.
Support Care Cancer
September 2023
Department of Palliative Medicine, Akershus University Hospital, Sykehusveien 25, 1478, Lørenskog, Norway.
Purpose: Some cancer patients in palliative care require intravenous administration of symptom relieving drugs. Peripherally inserted central catheters (PICCs) and midline catheters (MCs) provide easy and accessible intravenous access. However, limited evidence supports the use of these devices in palliative care.
View Article and Find Full Text PDFSQ HDM Sublingual Immunotherapy Tablet for the Treatment of HDM Allergic Rhinitis and Asthma Improves Subjective Sleepiness and Insomnia: An Exploratory Analysis of the Real-life CARIOCA Study.
J Investig Allergol Clin Immunol
October 2024
Department of Respiratory Diseases, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, France.
Background: Knowledge of the effectiveness of house dust mite (HDM) sublingual immunotherapy (SLIT) in allergic rhinitis (AR) and asthma associated sleep disorders remains incomplete. A noninterventional study was conducted to assess the effect of the standardized quality (SQ) HDM SLIT tablet on safety and symptoms in adults with respiratory allergies caused by HDM. The study also assessed the status of insomnia and daytime sleepiness in patients with AR and/or asthma-associated sleep disorders treated with the SQ HDM SLIT tablet.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!